Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

The Persistent Effects of Youth Savings Reminders: Experimental Evidence from Text-Message Campaigns in Colombia.

Rodríguez C, Saavedra JE.

J Dev Econ. 2019 Jun;139:135-156. doi: 10.1016/j.jdeveco.2019.03.001. Epub 2019 Mar 8.

PMID:
31007350
2.

The nitric oxide donor JS-K sensitizes U87 glioma cells to repetitive irradiation.

Heckler M, Osterberg N, Guenzle J, Thiede-Stan NK, Reichardt W, Weidensteiner C, Saavedra JE, Weyerbrock A.

Tumour Biol. 2017 Jun;39(6):1010428317703922. doi: 10.1177/1010428317703922.

PMID:
28653883
3.

JS-K, a nitric oxide prodrug, induces DNA damage and apoptosis in HBV-positive hepatocellular carcinoma HepG2.2.15 cell.

Liu Z, Li G, Gou Y, Xiao D, Luo G, Saavedra JE, Liu J, Wang H.

Biomed Pharmacother. 2017 Aug;92:989-997. doi: 10.1016/j.biopha.2017.05.141. Epub 2017 Jun 8.

PMID:
28605880
4.

ATF3 reduces migration capacity by regulation of matrix metalloproteinases via NFκB and STAT3 inhibition in glioblastoma.

Guenzle J, Wolf LJ, Garrelfs NW, Goeldner JM, Osterberg N, Schindler CR, Saavedra JE, Weyerbrock A.

Cell Death Discov. 2017 Feb 27;3:17006. doi: 10.1038/cddiscovery.2017.6. eCollection 2017.

5.

Effects of JS-K, a novel anti-cancer nitric oxide prodrug, on gene expression in human hepatoma Hep3B cells.

Dong R, Wang X, Wang H, Liu Z, Liu J, Saavedra JE.

Biomed Pharmacother. 2017 Apr;88:367-373. doi: 10.1016/j.biopha.2017.01.080. Epub 2017 Jan 22.

PMID:
28122301
6.

Nitric oxide released from JS-K induces cell death by mitotic catastrophe as part of necrosis in glioblastoma multiforme.

Günzle J, Osterberg N, Saavedra JE, Weyerbrock A.

Cell Death Dis. 2016 Sep 1;7(9):e2349. doi: 10.1038/cddis.2016.254.

7.

[Perceptions on healthcare in people with self-identified mental health problems in the rural areas of Peru].

Saavedra JE, Uchofen-Herrera V.

Rev Peru Med Exp Salud Publica. 2016 Oct-Dec;33(4):785-793. doi: 10.17843/rpmesp.2016.334.2566. Spanish.

8.

Disentangling Disadvantage: Can We Distinguish Good Teaching from Classroom Composition?

Zamarro G, Engberg J, Saavedra JE, Steele J.

J Res Educ Eff. 2015;8(1):84-111. Epub 2015 Jan 12.

9.

Key bioactive reaction products of the NO/H2S interaction are S/N-hybrid species, polysulfides, and nitroxyl.

Cortese-Krott MM, Kuhnle GG, Dyson A, Fernandez BO, Grman M, DuMond JF, Barrow MP, McLeod G, Nakagawa H, Ondrias K, Nagy P, King SB, Saavedra JE, Keefer LK, Singer M, Kelm M, Butler AR, Feelisch M.

Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):E4651-60. doi: 10.1073/pnas.1509277112. Epub 2015 Jul 29.

10.

PABA/NO lead optimization: Improved targeting of cytotoxicity to glutathione S-transferase P1-overexpressing cancer cells.

Kim Y, Maciag AE, Cao Z, Deschamps JR, Saavedra JE, Keefer LK, Holland RJ.

Bioorg Med Chem. 2015 Aug 1;23(15):4980-8. doi: 10.1016/j.bmc.2015.05.020. Epub 2015 May 19.

PMID:
26043946
11.

Hepatoselective Nitric Oxide (NO) Donors, V-PYRRO/NO and V-PROLI/NO, in Nonalcoholic Fatty Liver Disease: A Comparison of Antisteatotic Effects with the Biotransformation and Pharmacokinetics.

Kus K, Walczak M, Maslak E, Zakrzewska A, Gonciarz-Dytman A, Zabielski P, Sitek B, Wandzel K, Kij A, Chabowski A, Holland RJ, Saavedra JE, Keefer LK, Chlopicki S.

Drug Metab Dispos. 2015 Jul;43(7):1028-36. doi: 10.1124/dmd.115.063388. Epub 2015 Apr 13.

PMID:
25870102
13.

The liver-selective NO donor, V-PYRRO/NO, protects against liver steatosis and improves postprandial glucose tolerance in mice fed high fat diet.

Maslak E, Zabielski P, Kochan K, Kus K, Jasztal A, Sitek B, Proniewski B, Wojcik T, Gula K, Kij A, Walczak M, Baranska M, Chabowski A, Holland RJ, Saavedra JE, Keefer LK, Chlopicki S.

Biochem Pharmacol. 2015 Feb 1;93(3):389-400. doi: 10.1016/j.bcp.2014.12.004. Epub 2014 Dec 19.

PMID:
25534988
14.

Direct reaction of amides with nitric oxide to form diazeniumdiolates.

Holland RJ, Klose JR, Deschamps JR, Cao Z, Keefer LK, Saavedra JE.

J Org Chem. 2014 Oct 3;79(19):9389-93. doi: 10.1021/jo501670e. Epub 2014 Sep 22.

15.

Aminolysis of an N-diazeniumdiolated amidine as an approach to diazeniumdiolated ammonia.

Biswas D, Hrabie JA, Saavedra JE, Cao Z, Keefer LK, Ivanic J, Holland RJ.

J Org Chem. 2014 May 16;79(10):4512-6. doi: 10.1021/jo500551n. Epub 2014 May 5.

16.

Nitric oxide (NO) releasing poly ADP-ribose polymerase 1 (PARP-1) inhibitors targeted to glutathione S-transferase P1-overexpressing cancer cells.

Maciag AE, Holland RJ, Kim Y, Kumari V, Luthers CE, Sehareen WS, Biswas D, Morris NL, Ji X, Anderson LM, Saavedra JE, Keefer LK.

J Med Chem. 2014 Mar 27;57(6):2292-302. doi: 10.1021/jm401550d. Epub 2014 Feb 25.

17.

Mechanism of action for the cytotoxic effects of the nitric oxide prodrug JS-K in murine erythroleukemia cells.

Kaczmarek MZ, Holland RJ, Lavanier SA, Troxler JA, Fesenkova VI, Hanson CA, Cmarik JL, Saavedra JE, Keefer LK, Ruscetti SK.

Leuk Res. 2014 Mar;38(3):377-82. doi: 10.1016/j.leukres.2013.12.002. Epub 2013 Dec 12.

18.

Enzymatic generation of the NO/HNO-releasing IPA/NO anion at controlled rates in physiological media using β-galactosidase.

Holland RJ, Paulisch R, Cao Z, Keefer LK, Saavedra JE, Donzelli S.

Nitric Oxide. 2013 Nov 30;35:131-6. doi: 10.1016/j.niox.2013.10.003. Epub 2013 Oct 11.

19.

Nitric oxide-releasing prodrug triggers cancer cell death through deregulation of cellular redox balance.

Maciag AE, Holland RJ, Robert Cheng YS, Rodriguez LG, Saavedra JE, Anderson LM, Keefer LK.

Redox Biol. 2013 Feb 1;1:115-24. doi: 10.1016/j.redox.2012.12.002. eCollection 2013.

20.

O2-Protected Diazeniumdiolate-Modified Silica Nanoparticles for Extended Nitric Oxide Release from Dental Composites.

Carpenter AW, Reighard KP, Saavedra JE, Schoenfisch MH.

Biomater Sci. 2013 May 1;1(5):456-459.

21.

Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI.

Weidensteiner C, Reichardt W, Shami PJ, Saavedra JE, Keefer LK, Baumer B, Werres A, Jasinski R, Osterberg N, Weyerbrock A.

Nitric Oxide. 2013 Apr 1;30:17-25. doi: 10.1016/j.niox.2013.01.003. Epub 2013 Jan 28.

22.

O2-functionalized methylamine diazeniumdiolates: evidence for E ⇄ Z equilibration in an acyclic system.

Biswas D, Holland RJ, Deschamps JR, Cao Z, Keefer LK, Saavedra JE.

J Org Chem. 2012 Dec 7;77(23):10804-10. doi: 10.1021/jo3020837. Epub 2012 Nov 20.

PMID:
23137026
23.

Cross-linking protein glutathionylation mediated by O2-arylated bis-diazeniumdiolate "Double JS-K".

Holland RJ, Maciag AE, Kumar V, Shi L, Saavedra JE, Prud'homme RK, Chakrapani H, Keefer LK.

Chem Res Toxicol. 2012 Dec 17;25(12):2670-7. doi: 10.1021/tx3003142. Epub 2012 Nov 9.

24.

Nitrous oxide as a primary product in base-mediated β-elimination reactions of diazeniumdiolated benzylamine derivatives.

Biswas D, Cao Z, Keefer LK, Saavedra JE.

Chem Commun (Camb). 2012 Jun 14;48(47):5931-3. doi: 10.1039/c2cc32284f. Epub 2012 May 9.

PMID:
22572739
25.

Structural modifications modulate stability of glutathione-activated arylated diazeniumdiolate prodrugs.

Nandurdikar RS, Maciag AE, Holland RJ, Cao Z, Shami PJ, Anderson LM, Keefer LK, Saavedra JE.

Bioorg Med Chem. 2012 May 1;20(9):3094-9. doi: 10.1016/j.bmc.2012.02.045. Epub 2012 Mar 9.

26.

Diazeniumdiolated carbamates: a novel class of nitric oxide donors.

Nandurdikar RS, Maciag AE, Cao Z, Keefer LK, Saavedra JE.

Bioorg Med Chem. 2012 Mar 15;20(6):2025-9. doi: 10.1016/j.bmc.2012.01.046. Epub 2012 Feb 4.

27.

Thiol Modification By Pharmacologically Active Agents of the Diazeniumdiolate Class.

Maciag AE, Holland RJ, Saavedra JE, Chakrapani H, Shami PJ, Keefer LK.

For Immunopathol Dis Therap. 2012;3(2):91-95.

28.

Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs.

Maciag AE, Nandurdikar RS, Hong SY, Chakrapani H, Diwan B, Morris NL, Shami PJ, Shiao YH, Anderson LM, Keefer LK, Saavedra JE.

J Med Chem. 2011 Nov 24;54(22):7751-8. doi: 10.1021/jm2004128. Epub 2011 Oct 28.

29.

JS-K, a glutathione S-transferase-activated nitric oxide donor with antineoplastic activity in malignant gliomas.

Weyerbrock A, Osterberg N, Psarras N, Baumer B, Kogias E, Werres A, Bette S, Saavedra JE, Keefer LK, Papazoglou A.

Neurosurgery. 2012 Feb;70(2):497-510; discussion 510. doi: 10.1227/NEU.0b013e31823209cf.

30.

Nitric oxide donor, V-PROLI/NO, provides protection against arsenical induced toxicity in rat liver cells: requirement for Cyp1a1.

Qu W, Cheng L, Dill AL, Saavedra JE, Hong SY, Keefer LK, Waalkes MP.

Chem Biol Interact. 2011 Aug 15;193(1):88-96. doi: 10.1016/j.cbi.2011.05.005. Epub 2011 May 20.

31.

Novel protection-deprotection strategies in diazeniumdiolate chemistry: synthesis of V-IPA/NO.

Nandurdikar RS, Keefer LK, Saavedra JE.

Chem Commun (Camb). 2011 Jun 21;47(23):6710-2. doi: 10.1039/c1cc12130h. Epub 2011 May 10.

PMID:
21556407
32.

Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-π-activated nitric oxide donor PABA/NO in malignant gliomas.

Kogias E, Osterberg N, Baumer B, Psarras N, Koentges C, Papazoglou A, Saavedra JE, Keefer LK, Weyerbrock A.

Int J Cancer. 2012 Mar 1;130(5):1184-94. doi: 10.1002/ijc.26106. Epub 2011 Jul 21.

33.

HNO and NO release from a primary amine-based diazeniumdiolate as a function of pH.

Salmon DJ, Torres de Holding CL, Thomas L, Peterson KV, Goodman GP, Saavedra JE, Srinivasan A, Davies KM, Keefer LK, Miranda KM.

Inorg Chem. 2011 Apr 18;50(8):3262-70. doi: 10.1021/ic101736e. Epub 2011 Mar 15.

34.

JS-K, a nitric oxide-releasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cells.

McMurtry V, Saavedra JE, Nieves-Alicea R, Simeone AM, Keefer LK, Tari AM.

Int J Oncol. 2011 Apr;38(4):963-71. doi: 10.3892/ijo.2011.925. Epub 2011 Jan 25.

PMID:
21271218
35.

Effect of nitric oxide on neointimal hyperplasia based on sex and hormone status.

Hogg ME, Varu VN, Vavra AK, Popowich DA, Banerjee MN, Martinez J, Jiang Q, Saavedra JE, Keefer LK, Kibbe MR.

Free Radic Biol Med. 2011 May 1;50(9):1065-74. doi: 10.1016/j.freeradbiomed.2011.01.016. Epub 2011 Jan 21.

36.

The Nitric Oxide Prodrug V-PROLI/NO Inhibits Cellular Uptake of Proline.

Hong SY, Borchert GL, Maciag AE, Nandurdikar RS, Saavedra JE, Keefer LK, Phang JM, Chakrapani H.

ACS Med Chem Lett. 2010 Nov 11;1(8):386-389.

37.

Tailored Synthesis of Nitric Oxide-Releasing Polyurethanes Using O-Protected Diazeniumdiolated Chain Extenders.

Reynolds MM, Saavedra JE, Showalter BM, Valdez CA, Shanklin AP, Oh BK, Keefer LK, Meyerhoff ME.

J Mater Chem. 2010 Jan 1;20(15):3107-2114.

38.

Differential effects of nitric oxide on blood-brain barrier integrity and cerebral blood flow in intracerebral C6 gliomas.

Weyerbrock A, Walbridge S, Saavedra JE, Keefer LK, Oldfield EH.

Neuro Oncol. 2011 Feb;13(2):203-11. doi: 10.1093/neuonc/noq161. Epub 2010 Nov 1.

39.

Dual mechanisms of HNO generation by a nitroxyl prodrug of the diazeniumdiolate (NONOate) class.

Andrei D, Salmon DJ, Donzelli S, Wahab A, Klose JR, Citro ML, Saavedra JE, Wink DA, Miranda KM, Keefer LK.

J Am Chem Soc. 2010 Nov 24;132(46):16526-32. doi: 10.1021/ja106552p. Epub 2010 Oct 29.

40.

The nitric oxide prodrug JS-K is effective against non-small-cell lung cancer cells in vitro and in vivo: involvement of reactive oxygen species.

Maciag AE, Chakrapani H, Saavedra JE, Morris NL, Holland RJ, Kosak KM, Shami PJ, Anderson LM, Keefer LK.

J Pharmacol Exp Ther. 2011 Feb;336(2):313-20. doi: 10.1124/jpet.110.174904. Epub 2010 Oct 20.

41.

"Click" reaction in conjunction with diazeniumdiolate chemistry: developing high-load nitric oxide donors.

Oladeinde OA, Hong SY, Holland RJ, Maciag AE, Keefer LK, Saavedra JE, Nandurdikar RS.

Org Lett. 2010 Oct 1;12(19):4256-9. doi: 10.1021/ol101645k.

42.

JS-K, a nitric oxide-releasing prodrug, modulates ß-catenin/TCF signaling in leukemic Jurkat cells: evidence of an S-nitrosylated mechanism.

Nath N, Chattopadhyay M, Pospishil L, Cieciura LZ, Goswami S, Kodela R, Saavedra JE, Keefer LK, Kashfi K.

Biochem Pharmacol. 2010 Dec 1;80(11):1641-9. doi: 10.1016/j.bcp.2010.08.011. Epub 2010 Aug 24.

PMID:
20797387
43.

JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo.

Kiziltepe T, Anderson KC, Kutok JL, Jia L, Boucher KM, Saavedra JE, Keefer LK, Shami PJ.

J Pharm Pharmacol. 2010 Jan;62(1):145-51. doi: 10.1211/jpp.62.01.0017.

44.

Insulin enhances the effect of nitric oxide at inhibiting neointimal hyperplasia in a rat model of type 1 diabetes.

Varu VN, Ahanchi SS, Hogg ME, Bhikhapurwala HA, Chen A, Popowich DA, Vavra AK, Martinez J, Jiang Q, Saavedra JE, Hrabie JA, Keefer LK, Kibbe MR.

Am J Physiol Heart Circ Physiol. 2010 Sep;299(3):H772-9. doi: 10.1152/ajpheart.01234.2009. Epub 2010 Jun 18.

45.

Isopropylamine NONOate (IPA/NO) moderates neointimal hyperplasia following vascular injury.

Tsihlis ND, Murar J, Kapadia MR, Ahanchi SS, Oustwani CS, Saavedra JE, Keefer LK, Kibbe MR.

J Vasc Surg. 2010 May;51(5):1248-59. doi: 10.1016/j.jvs.2009.12.028. Epub 2010 Mar 11.

46.

Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and Double JS-K, through incorporation into PEG-protected nanoparticles.

Kumar V, Hong SY, Maciag AE, Saavedra JE, Adamson DH, Prud'homme RK, Keefer LK, Chakrapani H.

Mol Pharm. 2010 Feb 1;7(1):291-8. doi: 10.1021/mp900245h.

47.

Glycosylated PROLI/NO derivatives as nitric oxide prodrugs.

Nandurdikar RS, Maciag AE, Hong SY, Chakrapani H, Citro ML, Keefer LK, Saavedra JE.

Org Lett. 2010 Jan 1;12(1):56-9. doi: 10.1021/ol902481s.

48.

The nitric oxide prodrug JS-K and its structural analogues as cancer therapeutic agents.

Maciag AE, Saavedra JE, Chakrapani H.

Anticancer Agents Med Chem. 2009 Sep;9(7):798-803. Epub 2009 Sep 1. Review.

PMID:
19538173
49.

Synthesis and evaluation of piperazine and homopiperazine analogues of JS-K, an anti-cancer lead compound.

Nandurdikar RS, Maciag AE, Citro ML, Shami PJ, Keefer LK, Saavedra JE, Chakrapani H.

Bioorg Med Chem Lett. 2009 May 15;19(10):2760-2. doi: 10.1016/j.bmcl.2009.03.115. Epub 2009 Mar 28.

50.

Gene expression profiling for nitric oxide prodrug JS-K to kill HL-60 myeloid leukemia cells.

Liu J, Malavya S, Wang X, Saavedra JE, Keefer LK, Tokar E, Qu W, Waalkes MP, Shami PJ.

Genomics. 2009 Jul;94(1):32-8. doi: 10.1016/j.ygeno.2009.03.005. Epub 2009 Apr 5.

Supplemental Content

Loading ...
Support Center